Scarica l'app Stockscreener
7.96
1.53%
0.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.84
Aprire:
$7.88
Volume 24 ore:
1.04M
Relative Volume:
0.74
Capitalizzazione di mercato:
$1.08B
Reddito:
$175.51M
Utile/perdita netta:
$-78.02M
Rapporto P/E:
-15.02
EPS:
-0.53
Flusso di cassa netto:
$-34.18M
1 W Prestazione:
-1.49%
1M Prestazione:
-3.05%
6M Prestazione:
-12.53%
1 anno Prestazione:
+46.86%
Intervallo 1D:
$7.80
$8.0089
Intervallo di 1 settimana:
$7.77
$8.25
Portata 52W:
$5.15
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Confronta AUPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
7.96 | 1.10B | 175.51M | -78.02M | -34.18M | -0.53 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
Is The Options Market Predicting A Spike In Aurinia Pharmaceuticals (AUPH) Stock? - Barchart.com
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial Results | AUPH Stock News - GuruFocus
Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
Aurinia Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Transcript : Aurinia Pharmaceuticals Inc.Shareholder/Analyst Call - marketscreener.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN
Aurinia Pharmaceuticals Financial Update and Strategic Growth Plans - Zenopa
Aurinia Pharmaceuticals (AUPH) Reports Strong Q1 Earnings Beat - GuruFocus
Aurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves - MSN
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Company News for May 13, 2025 - Yahoo Finance
Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Document - SEC.gov
Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Aurinia: Q1 Earnings Snapshot - MySA
Aurinia Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga
Leerink maintains Aurinia stock Outperform with $10 target - Investing.com
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens - Investing.com India
AUPH Reports Q1 Revenue Exceeding Expectations with Strong Outlo - GuruFocus
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Aurinia Pharmaceuticals' Q1 Swings to Profit, Revenue Rises; Reiterates 2025 Revenue Guidance - marketscreener.com
Aurinia Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Aurinia Pharmaceuticals Inc. Reiterates Guidance for the Full Year 2025 - marketscreener.com
Aurinia Pharmaceuticals Reports Strong First Quarter 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 - Business Wire
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st
How the (AUPH) price action is used to our Advantage - news.stocktradersdaily.com
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 - BioSpace
Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks
ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting - TipRanks
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - The Globe and Mail
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - BioSpace
Aurinia Pharmaceuticals (AUPH) Gains Support from ISS for Board - GuruFocus
Aurinia Pharmaceuticals Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):